Physician profile
Rogelio Perez
NPI 1265456438
$8,882.57
in general payments reported to CMS, 2019-2025
37 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $2,056 · 2021: $2,148 · 2022: $463 · 2023: $921 · 2024: $1,522 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,048.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $2,540.32 | 2020-2024 | Aemcolo, Talicia |
| Abbvie INC. | $1,326.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $834.99 | 2020-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $580.71 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $518.19 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $393.01 | 2023-2025 | |
| Ardelyx, INC. | $343.60 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $266.98 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $228.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $186.92 | 2020-2023 | Linzess |
| Medtronic, INC. | $170.97 | 2024 | Gi Genius |
| Regeneron Healthcare Solutions, INC. | $141.12 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $121.86 | 2024-2025 | Voquezna |
| Celgene Corporation | $119.61 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $110.19 | 2024-2025 | Vowst |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $99.86 | 2021-2025 | Pancreaze |
| Lilly USA, LLC | $97.34 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $80.73 | 2025 | General - Therapies, Axonics |
| Intercept Pharmaceuticals, INC. | $78.87 | 2021-2023 | Ocaliva |
| Cook Medical LLC | $75.45 | 2019 | |
| Gilead Sciences, INC. | $71.24 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $67.91 | 2019-2020 | |
| Evoke Pharma, INC. | $59.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.80 | 2021 | |
| Braintree Laboratories, INC. | $43.63 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $38.09 | 2025 | Terlivaz |
| Daiichi Sankyo INC. | $29.65 | 2022 | |
| Novo Nordisk INC | $29.28 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $27.31 | 2020-2023 | |
| Teleflex LLC | $25.00 | 2025 | Solesta |
| Celltrion USA INC. | $24.36 | 2024 | Vegzelma |
| Fresenius Kabi USA, LLC | $23.20 | 2023 | |
| Pfizer INC. | $20.68 | 2021 | |
| Axonics, INC. | $19.88 | 2024 | Axonics |
| Endo Pharmaceuticals INC. | $17.36 | 2019 | |
| Amgen INC. | $14.41 | 2023 | Avsola |
| Allergan, INC. | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rogelio Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.